IP Library Granted Patent US 7,582,767
Granted Patent B2
US 7,582,767 · App. 11/447,524 · Granted Sep 1, 2009

Substituted sulphonamide compound and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,582,767
App. No.
11/447,524
Granted
Sep 1, 2009
Kind
B2
Abstract

The present invention relates to compounds of the formula (I), wherein R 1 and R 2 are as defined in the description; to pharmaceutical formulations comprising these compounds, and to the use of the compounds for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, and/or CNS disorders, to achieve reduction of body weight and/or body weight gain.

Claims (13)

1. A compound of the formula (I):

or a pharmaceutically acceptable salt thereof, wherein either:

R 1 is methoxy and R 2 is methyl; or

R 1 is methoxy and R 2 is hydroxymethyl; or

R 1 is hydroxyl and R 2 is methyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is methoxy and R 2 is methyl.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is methoxy and R 2 is hydroxymethyl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is hydroxyl and R 2 is methyl.

5. A pharmaceutical formulation comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof as an active ingredient, in combination with a pharmaceutically acceptable diluent or carrier.

6. A method for treatment of obesity, comprising administering an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

7. A method for treatment of type II diabetes, comprising administering an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

8. A method of treating type II diabetes by reducing body weight or reducing body weight gain, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

9. A method for modulating 5-HT 6 receptor activity, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2011
From: BIOVITRUM AB (PUBL)
To: PROXIMAGEN NEUROSCIENCE PLC
Reel/Frame 026497/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2011
From: PROXIMAGEN NEUROSCIENCE PLC
To: PROXIMAGEN LIMITED
Reel/Frame 026497/0177 →
CHANGE OF NAME Recorded Jun 20, 2011
From: BIOVITRUM AB
To: BIOVITRUM AB (PUBL)
Reel/Frame 026480/0454 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2006
From: CALDIROLA, PATRIZIA; JOHANSSON, GARY; SUTIN, LORI
To: BIOVITRUM AB
Reel/Frame 018190/0121 →